Par R&D joint venture
Par is providing financial assistance to TL Pharmaceutical Corp. for development of the company's drugs. In return, Par may choose TLPC products for sponsorship during the next five years and take share in profits from their sales during their entire market life. The Paramus, N.J.-based TLPC is developing drugs "with technologies that facilitate their ability to penetrate biological membranes including the blood-brain barrier," Par said.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.